BioXcel Therapeutics (BTAI) Short Interest Ratio & Short Volume → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Free BTAI Stock Alerts $2.71 -0.26 (-8.75%) (As of 04/24/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability BioXcel Therapeutics Short Interest DataCurrent Short Volume2,490,000 sharesPrevious Short Volume3,140,000 sharesChange Vs. Previous Month-20.70%Dollar Volume Sold Short$7.02 millionShort Interest Ratio / Days to Cover1.7Last Record DateMarch 31, 2024Outstanding Shares37,030,000 sharesFloat Size23,620,000 sharesShort Percent of Float10.54%Today's Trading Volume879,848 sharesAverage Trading Volume1,317,763 sharesToday's Volume Vs. Average67% Short Selling BioXcel Therapeutics ? Sign up to receive the latest short interest report for BioXcel Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatBTAI Short Interest Over TimeBTAI Days to Cover Over TimeBTAI Percentage of Float Shorted Over Time Ad GoldenCrest MetalsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.Learn More Now BioXcel Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/20242,490,000 shares $7.02 million -20.7%10.5%1.7 $2.82 3/15/20243,140,000 shares $8.42 million -20.9%14.6%2.1 $2.68 2/29/20243,970,000 shares $12.62 million -46.8%18.7%2.6 $3.18 2/15/20247,460,000 shares $26.78 million +203.3%35.2%4.9 $3.59 1/31/20242,460,000 shares $7.92 million -17.5%11.9%2.1 $3.22 1/15/20242,980,000 shares $7.84 million +0.3%14.4%1.1 $2.63 Get the Latest News and Ratings for BTAI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/31/20232,970,000 shares $8.76 million +3.5%14.7%1 $2.95 12/15/20232,870,000 shares $9.30 million -16.6%14.2%0.9 $3.24 11/30/20233,440,000 shares $13.07 million -32.3%17.0%1.1 $3.80 11/15/20235,080,000 shares $22.35 million -12.6%25.1%1.6 $4.40 10/31/20235,810,000 shares $23.33 million +16.9%28.8%1.9 $4.02 10/15/20234,970,000 shares $15.56 million +38.8%24.6%3.6 $3.13 9/30/20233,580,000 shares $9.06 million -24.6%17.7%2.4 $2.53 9/15/20234,750,000 shares $15.87 million +8.0%23.5%1.6 $3.34 8/31/20234,400,000 shares $16.63 million -34.8%21.8%1.5 $3.78 8/15/20236,750,000 shares $27.95 million -4.1%33.5%2.3 $4.14 7/31/20237,040,000 shares $64.35 million -18.8%35.0%2.7 $9.14 7/15/20238,670,000 shares $89.30 million +69.0%43.1%3.5 $10.30 6/30/20235,130,000 shares $34.17 million +12.3%25.5%2.2 $6.66 6/15/20234,570,000 shares $98.26 million +22.9%22.7%8.3 $21.50 5/31/20233,720,000 shares $66.74 million +11.0%18.5%6.2 $17.94 5/15/20233,350,000 shares $91.22 million -5.4%16.7%6.5 $27.23 4/30/20233,540,000 shares $72.99 million -5.1%17.7%6.9 $20.62 4/15/20233,730,000 shares $69.90 million +3.6%18.6%7.4 $18.74 3/31/20233,600,000 shares $67.18 million +21.2%18.3%7.2 $18.66 3/15/20232,970,000 shares $58.21 million +5.7%15.1%6.3 $19.60 2/28/20232,810,000 shares $89.70 million +8.9%14.7%8 $31.92 2/15/20232,580,000 shares $84.29 million +5.3%13.5%7.6 $32.67 1/31/20232,450,000 shares $69.87 million +5.6%12.9%7.4 $28.52 1/15/20232,320,000 shares $67.14 million -3.3%12.2%8.1 $28.94 12/30/20222,400,000 shares $51.55 million +10.1%12.6%9.4 $21.48 12/15/20222,180,000 shares $44.04 million -4.4%11.5%9 $20.20 11/30/20222,280,000 shares $37.78 million -3.4%12.0%10.2 $16.57 11/15/20222,360,000 shares $38.00 million -6.7%12.4%10.9 $16.10 10/31/20222,530,000 shares $31.85 million -4.2%13.3%11.7 $12.59 10/15/20222,640,000 shares $27.06 million -5.7%13.9%11.1 $10.25 9/30/20222,800,000 shares $33.10 million -2.1%14.7%10.4 $11.82 9/15/20222,860,000 shares $37.95 million -2.4%15.0%8.5 $13.27 8/31/20222,930,000 shares $40.08 million -0.3%15.4%6.9 $13.68 8/15/20222,940,000 shares $44.86 million +7.7%15.5%6.1 $15.26Pentagon contract could send this $2 AI stock soaring (Ad)Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> BTAI Short Interest - Frequently Asked Questions What is BioXcel Therapeutics' current short interest? Short interest is the volume of BioXcel Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 31st, traders have sold 2,490,000 shares of BTAI short. 10.54% of BioXcel Therapeutics' shares are currently sold short. Learn More on BioXcel Therapeutics' current short interest. What is a good short interest ratio for BioXcel Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BTAI shares currently have a short interest ratio of 2.0. Learn More on BioXcel Therapeutics's short interest ratio. Which institutional investors are shorting BioXcel Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of BioXcel Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for BioXcel Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.54% of BioXcel Therapeutics' floating shares are currently sold short. Is BioXcel Therapeutics' short interest increasing or decreasing? BioXcel Therapeutics saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 2,490,000 shares, a decrease of 20.7% from the previous total of 3,140,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is BioXcel Therapeutics' float size? BioXcel Therapeutics currently has issued a total of 37,030,000 shares. Some of BioXcel Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. BioXcel Therapeutics currently has a public float of 23,620,000 shares. How does BioXcel Therapeutics' short interest compare to its competitors? 10.54% of BioXcel Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to BioXcel Therapeutics: Eton Pharmaceuticals, Inc. (0.98%), Chimerix, Inc. (1.56%), PMV Pharmaceuticals, Inc. (6.40%), Oncolytics Biotech Inc. (1.23%), Affimed (1.51%), Hookipa Pharma Inc (0.45%), YS Biopharma Co., Ltd. (0.54%), Spero Therapeutics, Inc. (1.21%), Clearside Biomedical, Inc. (0.30%), Aclaris Therapeutics, Inc. (6.89%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short BioXcel Therapeutics stock? Short selling BTAI is an investing strategy that aims to generate trading profit from BioXcel Therapeutics as its price is falling. BTAI shares are trading down $0.27 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against BioXcel Therapeutics? A short squeeze for BioXcel Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BTAI, which in turn drives the price of the stock up even further. How often is BioXcel Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BTAI, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: ETON Short Squeeze CMRX Short Squeeze PMVP Short Squeeze ONCY Short Squeeze AFMD Short Squeeze HOOK Short Squeeze YS Short Squeeze SPRO Short Squeeze CLSD Short Squeeze ACRS Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BTAI) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders